Health Industry Updates: Ebola Threat, Natera's Cancer Trials, and FDA Peptide Reviews
Published on: July 1, 2026, 2:28 a.m. | Source: Devdiscourse
The health sector is abuzz with Natera's new cancer trial, Ebola's economic impact, ongoing FDA reviews of alternative obesity drugs, Congo's challenge with an Ebola strain, and drug collaboration between the U.S. and China. Notably, global giant Zymeworks moves into the respiratory disease segment by acquiring Theravance Biopharma.
